This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

Clinical efficacy & safetyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-2 summaryPALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)SafetySafety overviewPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresIBRANCE long-term safetyGI and liver toxicitiesEffect of IBRANCE on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyRW evidenceValue of RWEWhat is real-world evidence?What is the value of RWE?P-REALITY and P-REALITY XP-REALITY OverviewP-REALITY OS and rwPFSP-REALITY X OverviewP-REALITY X OS and rwPFSIRISIRIS OverviewIRIS PFS and OSPOLARIS POLARIS OverviewPOLARIS Patient-Reported OutcomesMADELINEMADELINE OverviewMADELINE Patient CharacteristicsMADELINE Patient-Reported OutcomesPalomAGEPalomAGE OverviewRWE in Older Patients with mBCP-VERIFYP-VERIFY StudyPatient-reported outcomesPALOMA-2: FACT-B scoresPALOMA-3: EORTC QLQ-C30 scoresPALOMA-3: Time to deterioration in pain symptomsDosingRecommended dosing scheduleRecommended dose modifications for AEsMonitoringOne scheduled monitoring provisionPrescribing Information ResourcesMaterials
PALOMA-3 overall survival (secondary endpoint) In PALOMA-3, OS results demonstrated a numerical, but non-statistically significant difference, in favour of IBRANCE3

The PALOMA-3 OS final analysis of IBRANCE in combination with fulvestrant in 1st line or later demonstrated a numerical difference in favour of IBRANCE in combination with fulvestrant vs placebo + fulvestrant that did not reach statistical significance1,2

The difference in median OS with IBRANCE in combination with fulvestrant (not statistically significant)1 was similar to the improvement in mPFS previously seen with the addition of IBRANCE to fulvestrant in PALOMA-31,3

PALOMA-3 OS Kaplan-Meier Curve1,2

Adapted from IBRANCE SmPC2 and Turner NC, et al. 2018.1
Data cut-off date: April 13, 2018.

* Not statistically significant at the prespecified significance level of 0.0235 (1-sided).2 
† 1-sided p-value from the log-rank test stratified by the presence of visceral metastases and sensitivity to prior endocrine therapy per randomisation.2

The final updated non-prespecified OS analysis demonstrated a numerical difference in mOS in favor of IBRANCE + fulvestrant, at >6 years median follow-up.⁴

Data cut-off date: August 17, 2020. 

Explore More
PALOMA-2

See PALOMA-2 overall survival data

 Learn more Expert opinion

What do experts think about the efficacy of IBRANCE?

Expert opinion (Placeholder for local video content)

 Learn more
CI = confidence interval; ET = endocrine therapy; FUL = fulvestrant; HR = hazard ratio; HR+/HER2- = hormone receptor-positive/human epidermal growth factor receptor 2-negative; mBC = metastatic breast cancer; n = number of patients; OS = overall survival; PLA = placebo; SmPC = Summary of Product Characteristics.
References:Turner NC, et al. N Engl J Med. 2018;379(20): 1926-1936.IBRANCE Summary of Product Characteristics.Cristofanilli M, et al. ASCO 2021; Oral presentation 1000.Cristofanilli et al. Clin Cancer Res; 28(16) August 15, 2022.
PALOMA-3 IBRANCE in the real-world setting

Discover how patients responded to IBRANCE combination therapy in the real-world setting

 Find out more
IBRANCE Summary of Product Characteristics Product Characteristics Loading

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0695. January 2024

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0832. October 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0832. October 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0832. October 2024